Tianyin Pharmaceutical Co., Inc. Provides Fiscal 201...(million generating strong brand awarenes...),Health

Date:6/18/2009

million, generating strong brand awareness and creating further demand for our flagship and other proprietary products. In addition, we instituted a cash dividend which enables our shareholders to participate in our profitability each quarter and is something we hope to increase in the future as the Company grows."

"During fiscal 2009, we received approval from the Chinese State Food and Drug Administration (SFDA) for ten new products. These introductions are critical to our growth strategy and our enhanced product portfolio positions us for accelerating revenues during fiscal 2010. We significantly grew the sales of our flagship Gingko Mihuan through successful tenders and greatly expanded the number of distributors actively marketing this product. We also completed the build-out of our new production facility and are currently initiating GMP certification process. The recent passage of the Healthcare Reform Act was a significant milestone and will culminate into approximately $126 Billion being spent by the government during the next 3 years to bring universal healthcare to all Chinese citizens. As a further component, the central government openly stated its support for Traditional Chinese Medicine (TCM), which will receive additional incentives and funding; this is a policy that we believe will have significant positive implications for our industry," Dr. Jiang stated.

Fiscal Year 2010 Financial Guidance

For fiscal year 2010 which ends June 30, 2010, Tianyin forecasts that revenues will exceed $59 million with net income at least $10.5 million, representing approximately 40% and 42% growth compared to fiscal 2009 forecasts. Management anticipates that approximately $7 million, or 12% of total revenues will result from products which were launched during fiscal 2009, while it is anticipated that sales of the Company's flagship product, Ginko Mihuan, will grow by approximately 80% to $20 million f
'/>"/>

SOURCE Tianyin Pharmaceutical, Co., Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
5. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
6. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
8. Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
9. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets
10. Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program
11. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST